A detailed history of Ubs Group Ag transactions in Exagen Inc. stock. As of the latest transaction made, Ubs Group Ag holds 62,516 shares of XGN stock, worth $113,779. This represents 0.0% of its overall portfolio holdings.

Number of Shares
62,516
Previous 62,409 0.17%
Holding current value
$113,779
Previous $124,000 20.16%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$1.42 - $2.3 $151 - $246
107 Added 0.17%
62,516 $99,000
Q4 2023

Feb 09, 2024

SELL
$1.45 - $2.39 $99,214 - $163,533
-68,424 Reduced 52.3%
62,409 $124,000
Q1 2023

May 12, 2023

SELL
$2.23 - $2.9 $13,413 - $17,443
-6,015 Reduced 4.4%
130,833 $317,000
Q4 2022

Feb 08, 2023

BUY
$2.1 - $3.4 $73 - $119
35 Added 0.03%
136,848 $328,000
Q3 2022

Nov 10, 2022

BUY
$3.43 - $8.68 $17,643 - $44,649
5,144 Added 3.91%
136,813 $370,000
Q2 2022

Aug 10, 2022

SELL
$4.18 - $7.74 $1,245 - $2,306
-298 Reduced 0.23%
131,669 $756,000
Q1 2022

May 16, 2022

SELL
$7.12 - $11.06 $27,226 - $42,293
-3,824 Reduced 2.82%
131,967 $1.06 Million
Q4 2021

Feb 14, 2022

BUY
$8.97 - $14.08 $52,851 - $82,959
5,892 Added 4.54%
135,791 $1.58 Million
Q3 2021

Nov 15, 2021

BUY
$10.25 - $15.21 $6,949 - $10,312
678 Added 0.52%
129,899 $1.77 Million
Q2 2021

Aug 13, 2021

SELL
$12.4 - $17.92 $41,440 - $59,888
-3,342 Reduced 2.52%
129,221 $1.94 Million
Q1 2021

May 12, 2021

BUY
$13.9 - $22.0 $1.83 Million - $2.9 Million
131,703 Added 15314.3%
132,563 $2.32 Million
Q4 2020

Feb 11, 2021

BUY
$11.19 - $16.05 $9,119 - $13,080
815 Added 1811.11%
860 $11,000
Q3 2020

Nov 12, 2020

SELL
$10.56 - $16.69 $15,480 - $24,467
-1,466 Reduced 97.02%
45 $0
Q2 2020

Jul 31, 2020

SELL
$11.0 - $16.7 $4,565 - $6,930
-415 Reduced 21.55%
1,511 $19,000
Q1 2020

May 01, 2020

SELL
$12.7 - $25.95 $27,470 - $56,129
-2,163 Reduced 52.9%
1,926 $31,000
Q4 2019

Feb 14, 2020

BUY
$12.61 - $28.48 $51,562 - $116,454
4,089 New
4,089 $104,000

Others Institutions Holding XGN

About EXAGEN INC.


  • Ticker XGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 16,260,400
  • Market Cap $29.6M
  • Description
  • Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus ery...
More about XGN
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.